Pricing

Pharmasset Inc (VRUS)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
303-A COLLEGE ROAD EAST PRINCETON, NJ 08540

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Are you looking for these stocks instead?

Stock Split History
DateRatio
2011-09-01 2:1
Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections. Its primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The company has three product candidates under development, which include Clevudine, an oral, once-daily pyrimidine nucleoside analog, which is under Phase III clinical trials for the treatment of chronic HBV infection; R7128, a pro-drug of PSI-6130 in Part 3 of a Phase I clinical trial for the treatment of HCV, through a collaboration with F. Hoffmann-LaRoche, Ltd. and Hoffmann-La Roche, Inc.; and Racivir, an oral, once-daily cytidine nucleoside analog, which has completed a Phase II clinical trial for the treatment of HIV. In addition, the company engages in the development of DFC, an oral, once-daily deoxycytidine nucleoside analog, for the treatment of HIV.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available